Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Patients with Neurodegenerative Proteinopathies Exhibit Altered Tryptophan Metabolism in the Serum and Cerebrospinal Fluid

M. Kaleta, E. Hényková, K. Menšíková, D. Friedecký, A. Kvasnička, K. Klíčová, D. Koníčková, M. Strnad, P. Kaňovský, O. Novák

. 2024 ; 15 (3) : 582-592. [pub] 20240109

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007191

Some pathological conditions affecting the human body can also disrupt metabolic pathways and thus alter the overall metabolic profile. Knowledge of metabolic disturbances in specific diseases could thus enable the differential diagnosis of otherwise similar conditions. This work therefore aimed to comprehensively characterize changes in tryptophan metabolism in selected neurodegenerative diseases. Levels of 18 tryptophan-related neuroactive substances were determined by high throughput and sensitive ultrahigh-performance liquid chromatography-tandem mass spectrometry in time-linked blood serum and cerebrospinal fluid samples from 100 age-matched participants belonging to five cohorts: healthy volunteers (n = 21) and patients with Lewy body disease (Parkinson's disease and dementia with Lewy bodies; n = 31), four-repeat tauopathy (progressive supranuclear palsy and corticobasal syndrome; n = 10), multiple system atrophy (n = 13), and Alzheimer's disease (n = 25). Although these conditions have different pathologies and clinical symptoms, the discovery of new biomarkers is still important. The most statistically significant differences (with p-values of ≤0.05 to ≤0.0001) between the study cohorts were observed for three tryptophan metabolites: l-kynurenine in cerebrospinal fluid and 3-hydroxy-l-kynurenine and 5-hydroxy-l-tryptophan in blood serum. This led to the discovery of distinctive correlation patterns between the profiled cerebrospinal fluid and serum metabolites that could provide a basis for the differential diagnosis of neurodegenerative tauopathies and synucleinopathies. However, further large-scale studies are needed to determine the direct involvement of these metabolites in the studied neuropathologies, their response to medication, and their potential therapeutic relevance.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007191
003      
CZ-PrNML
005      
20240423155759.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acschemneuro.3c00611 $2 doi
035    __
$a (PubMed)38194490
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kaleta, Michal $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000308752912
245    10
$a Patients with Neurodegenerative Proteinopathies Exhibit Altered Tryptophan Metabolism in the Serum and Cerebrospinal Fluid / $c M. Kaleta, E. Hényková, K. Menšíková, D. Friedecký, A. Kvasnička, K. Klíčová, D. Koníčková, M. Strnad, P. Kaňovský, O. Novák
520    9_
$a Some pathological conditions affecting the human body can also disrupt metabolic pathways and thus alter the overall metabolic profile. Knowledge of metabolic disturbances in specific diseases could thus enable the differential diagnosis of otherwise similar conditions. This work therefore aimed to comprehensively characterize changes in tryptophan metabolism in selected neurodegenerative diseases. Levels of 18 tryptophan-related neuroactive substances were determined by high throughput and sensitive ultrahigh-performance liquid chromatography-tandem mass spectrometry in time-linked blood serum and cerebrospinal fluid samples from 100 age-matched participants belonging to five cohorts: healthy volunteers (n = 21) and patients with Lewy body disease (Parkinson's disease and dementia with Lewy bodies; n = 31), four-repeat tauopathy (progressive supranuclear palsy and corticobasal syndrome; n = 10), multiple system atrophy (n = 13), and Alzheimer's disease (n = 25). Although these conditions have different pathologies and clinical symptoms, the discovery of new biomarkers is still important. The most statistically significant differences (with p-values of ≤0.05 to ≤0.0001) between the study cohorts were observed for three tryptophan metabolites: l-kynurenine in cerebrospinal fluid and 3-hydroxy-l-kynurenine and 5-hydroxy-l-tryptophan in blood serum. This led to the discovery of distinctive correlation patterns between the profiled cerebrospinal fluid and serum metabolites that could provide a basis for the differential diagnosis of neurodegenerative tauopathies and synucleinopathies. However, further large-scale studies are needed to determine the direct involvement of these metabolites in the studied neuropathologies, their response to medication, and their potential therapeutic relevance.
650    _2
$a lidé $7 D006801
650    _2
$a tryptofan $7 D014364
650    _2
$a kynurenin $7 D007737
650    _2
$a sérum $7 D044967
650    12
$a Alzheimerova nemoc $x diagnóza $7 D000544
650    12
$a tauopatie $7 D024801
650    12
$a poruchy proteostázy $7 D057165
650    _2
$a biologické markery $7 D015415
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hényková, Eva $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000340337786
700    1_
$a Menšíková, Kateřina $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic
700    1_
$a Friedecký, David $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Zdravotníků 248/7, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000234489073 $7 xx0142900
700    1_
$a Kvasnička, Aleš $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Zdravotníků 248/7, 779 00 Olomouc, Czech Republic $1 https://orcid.org/000000015973316X
700    1_
$a Klíčová, Kateřina $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000275284146
700    1_
$a Koníčková, Dorota $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000344460060
700    1_
$a Strnad, Miroslav $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/000000022806794X
700    1_
$a Kaňovský, Petr $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic
700    1_
$a Novák, Ondřej $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $1 https://orcid.org/0000000334520154 $7 xx0120183
773    0_
$w MED00193636 $t ACS chemical neuroscience $x 1948-7193 $g Roč. 15, č. 3 (2024), s. 582-592
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38194490 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155755 $b ABA008
999    __
$a ok $b bmc $g 2081274 $s 1216958
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 15 $c 3 $d 582-592 $e 20240109 $i 1948-7193 $m ACS chemical neuroscience $n ACS Chem Neurosci $x MED00193636
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...